Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
04:01pm, Friday, 06'th Dec 2024
– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
08:30am, Monday, 25'th Nov 2024
VANCOUVER, British Columbia and BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon to Present at Upcoming Investor Conferences
04:01pm, Wednesday, 13'th Nov 2024
VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
11:51am, Wednesday, 13'th Nov 2024
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript
10:49pm, Tuesday, 12'th Nov 2024
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President a
Xenon Reports Q3 2024 Financial Results and Business Update
04:01pm, Tuesday, 12'th Nov 2024
– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – P
Xenon to Report Q3 2024 Financial Results on November 12, 2024
04:01pm, Tuesday, 05'th Nov 2024
VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
04:28pm, Wednesday, 02'nd Oct 2024
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developin
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
08:30am, Monday, 09'th Sep 2024
VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Polarean Imaging appoints Xenon MRI specialist as its chief medical advisor
03:08am, Wednesday, 28'th Aug 2024
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has appointed Dr Chase Hall as chief medical advisor. An associate professor at the University of Kansas Medical Center, Hall specialises in pulmonary care
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
11:50am, Wednesday, 21'st Aug 2024
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript
12:10pm, Friday, 09'th Aug 2024
Xenon Pharmaceuticals, Inc. (NASDAQ:XENE ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Chad Fugere - VP, IR Ian Mortimer - President & CEO Chris Kenney - CMO Sherry
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
11:21am, Friday, 09'th Aug 2024
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Reports Q2 2024 Financial Results and Business Update
04:01pm, Thursday, 08'th Aug 2024
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 — MDD program on track with Phase 3 study expected to initiate in H2 2024— Multiple Kv7 and Nav1.7
Xenon to Report Q2 2024 Financial Results on August 8, 2024
04:01pm, Thursday, 01'st Aug 2024
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and deli
